Uganda Heart Institute
12
2
3
6
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 12 trials
100.0%
+13.5% vs industry average
8%
1 trials in Phase 3/4
17%
1 of 6 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (12)
The Genetic Basis of Congenital Heart Disease in Africa
Role: collaborator
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
Role: collaborator
A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop
Role: collaborator
Accelerating Delivery of rheUmatic Heart Disease Preventive iNterventions in Northern Uganda
Role: collaborator
Remote Ischaemic Conditioning in STEMI Patients in AFRICA
Role: collaborator
A Long-term Follow up Study for Patients Who Participated in the GOAL Trial (GOAL-Post)
Role: collaborator
Rheumatic Heart Disease Community Streptococcal Treatment Program "RESET"
Role: collaborator
Train the Trainer Curriculum to Scale up AI Supported Echo for RHD Screening in a Public Health System
Role: collaborator
Case Management and Peer Support Groups for Prophylaxis Adherence in Rheumatic Heart Disease
Role: collaborator
mHealth for Self-care of Heart Failure in Uganda
Role: collaborator
Leveraging the HIV Platform for Hypertension Control in Uganda (INTEGRATED HIV/HTN) STUDY
Role: collaborator
Determining the Impact of Penicillin in Latent RHD: The GOAL Trial
Role: collaborator
All 12 trials loaded